SCHEMBL9965091

SCHEMBL9965091

O=C(Nc1ccc(Cl)c(-c2cnc3ccccc3n2)c1)c1ccc(Cl)s1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 7/20 0.51
RAB9A P51151 7/20 0.51
KMT2A Q03164 7/20 0.51
KDM4E B2RXH2 5/20 0.51
MEN1 O00255 5/20 0.51
SMN1; SMN2 Q16637 4/20 0.51
CASP3 P42574 1/20 0.51
SENP8 Q96LD8 1/20 0.51
SENP7 Q9BQF6 1/20 0.51
SENP6 Q9GZR1 1/20 0.51
ALDH1A1 P00352 4/20 0.50
NFKB1 P19838 2/20 0.50
NFKB2 Q00653 2/20 0.50
RELA Q04206 2/20 0.50
NPSR1 Q6W5P4 1/20 0.50
RXFP1 Q9HBX9 1/20 0.50
TP53 P04637 1/20 0.50
MAPT P10636 2/20 0.47
CYP1A2 P05177 1/20 0.47
CYP3A4 P08684 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12679564 0.90 POLB (0.47) NPC1RAB9AKMT2AMEN1SMN1; SMN2
SCHEMBL12681301 0.90 NPC1 (0.50) NPC1RAB9AKMT2AKDM4EMEN1
SCHEMBL12681260 0.88 KMT2A (0.45) NPC1RAB9AKMT2AMEN1ALDH1A1
SCHEMBL12679595 0.85 KMT2A (0.55) NPC1RAB9AKMT2AKDM4EMEN1
SCHEMBL12679590 0.85 KMT2A (0.47) NPC1RAB9AKMT2AMEN1SMN1; SMN2
SCHEMBL12679606 0.83 KMT2A (0.65) NPC1RAB9AKMT2AMEN1SMN1; SMN2
SCHEMBL9965058 0.82 PKM (0.52) NPC1RAB9AKMT2AMEN1CASP3
SCHEMBL12679591 0.81 KMT2A (0.71) NPC1RAB9AKMT2AMEN1NPSR1
SCHEMBL12681346 0.81 RAB9A (0.64) NPC1RAB9AKMT2AKDM4EMEN1
SCHEMBL12679627 0.81 KMT2A (0.52) NPC1RAB9AKMT2AMEN1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8273743-B2 N-(4-chloro-3-(quinoxalin-3-yl)phenyl)-3,5-dimethoxybenzamide; for treating malignancies CURIS, INC. (US) 2012-09-25 US disclosed
EP-1745041-B1 QUINOXALINE INHIBITORS OF THE HEDGEHOG SIGNALLING PATHWAY GENENTECH INC (US) 2012-06-20 EP disclosed
US-20080261989-A1 Quinoxaline Inhibitors of the Hedgehog Signalling GENENTECH, INC. 2008-10-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080261989-A1 Quinoxaline Inhibitors of the Hedgehog Signalling SHH, NR4A2, NR4A3 NPC1 2120/4885RAB9A 2425/4885KMT2A 1167/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.